Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV) from a neutral rating to a buy rating in a research note published on Monday, Marketbeat.com reports. The brokerage currently has $16.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a buy rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a report on Tuesday, August 13th. Piper Sandler Companies reissued a buy rating and issued a $30.00 price target on shares of Acrivon Therapeutics in a research note on Friday, September 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Acrivon Therapeutics currently has a consensus rating of Buy and an average target price of $23.86.

Acrivon Therapeutics Trading Down 0.5 %

Shares of ACRV opened at $7.56 on Monday. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90. The stock has a market cap of $233.43 million, a P/E ratio of -2.65 and a beta of 0.81. The company has a 50-day moving average of $8.18 and a two-hundred day moving average of $7.68.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.08. As a group, analysts forecast that Acrivon Therapeutics will post -2.4 EPS for the current fiscal year.

Institutional Trading of Acrivon Therapeutics

Several large investors have recently added to or reduced their stakes in ACRV. Perceptive Advisors LLC increased its holdings in Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after buying an additional 2,353,000 shares during the last quarter. Sands Capital Ventures LLC increased its holdings in shares of Acrivon Therapeutics by 28.4% in the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock valued at $12,311,000 after acquiring an additional 470,000 shares during the last quarter. Marshall Wace LLP raised its position in shares of Acrivon Therapeutics by 58.8% during the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after acquiring an additional 351,397 shares in the last quarter. Baker BROS. Advisors LP bought a new position in Acrivon Therapeutics during the first quarter worth $378,000. Finally, Vanguard Group Inc. boosted its holdings in Acrivon Therapeutics by 6.6% in the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock worth $3,626,000 after purchasing an additional 31,208 shares during the period. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.